

F0 RJL22



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Anderson, et al.  
 Serial No. :  
 Filed :  
 For : Gene Therapy  
 Group : Unassigned  
 Examiner : Unassigned

Honorable Commissioner of  
 Patent and Trademarks  
 Washington, D.C. 20231

SIR:


In keeping with Applicants' duty under 37CFR1.56 to disclose information material to the patentability of the above-identified application, the following references, copies of which are enclosed, are hereby made of record.

- ✓ 1. Copy of a document submitted to the NIH Recombinant DNA Advisory Committee on April 24, 1987 which describes a proposal for gene therapy.
- ✓ 2. Copy of a protocol submitted to the NIH Recombinant DNA Advisory Committee on June 15, 1988, which describes a TIL protocol in which TIL cells were engineered with DNA encoding a marker.
- ✓ 3. Copy of a protocol dated March 13, 1990 for a proposed human DNA gene therapy treatment which was submitted to the NIH Recombinant DNA Advisory Committee.
- ✓ 4. Copy of a protocol for a proposed human TNF gene therapy treatment, which was submitted to the NIH Recombinant DNA Advisory Committee on July 6, 1990.
- ✓ 5. Moolten, Cancer Res., Vol. 46, pgs. 5276-5281 (1986).
- ✓ 6. Selden, Science, Vol. 236, pgs. 714-718.
- ✓ 7. Kohn, J. Cell. Biochem., Supp. 12 (B), Jan.-Feb. 1988, pg. 178.
- ✓ 8. Rosenberg, N. Engl. J. Med., Vol. 319, No. 25, pgs. 1676-1680 (December 22, 1988).
- ✓ 9. Rosenberg, Science, Vol. 233, pgs. 1318-1321 (September 19, 1986).

- ✓ 10. Kantoff, Proc. Nat. Acad. Sci., Vol. 83, pgs. 6563-6567 (1986).
11. Culver, J. Cell. Biochem., Supp. 12 (B), Jan.-Feb. 1988, pgs. 171.
- ✓ 12. Armentano, J. Virol., pgs. 1647-1650 (May 1987).

The above references also are listed on the attached Form PTO-1449. It is respectfully requested that the Examiner consider these references.

Respectfully submitted,



Raymond J. Lillie  
Reg. No. 31,778